Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.

British journal of cancer - 22 Nov 2016

Lam Siu W, Frederiks Charlotte N, van der Straaten Tahar, Honkoop Aafke H, Guchelaar Henk-Jan, Boven Epie

Abstract excerpt

BACKGROUND: The purpose of this study was to evaluate single-nucleotide polymorphisms (SNPs) in genes encoding key metabolising enzymes or involved in pharmacodynamics for possible associations with paclitaxel-induced peripheral neuropathy. METHODS: The study population consists of 188 women from the multicenter, randomised, phase II ATX trial (BOOG2006-06; EudraCT number 2006-006058-83) that received paclitaxel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP2C8

Share to Gene Frequency

Share to Microfilament Proteins

Share to Paclitaxel

Share to Peripheral Nervous System Diseases

Source

Open in PubMed Open full text

Identifiers

PMID: 27736846
DOI: 10.1038/bjc.2016.326
PMCID: PMC5129817

Genes

FGD4
EPHA5

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.PMID 27736846Read ↗

The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.Semantic proximity Read ↗

A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.Semantic proximity Read ↗

Polymorphism of <em>CYP3A4</em> and <em>ABCB1</em> genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxelSemantic proximity Read ↗

Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer.Semantic proximity Read ↗

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.Semantic proximity Read ↗

ABCB1 Single Nucleotide Polymorphism Genotypes as Predictors of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer.Semantic proximity Read ↗

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Semantic proximity Read ↗

Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting NeuropathySemantic proximity Read ↗

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.Semantic proximity Read ↗

Identification of Rare Variants in Candidate Genes Associated with Chemotherapy-Induced Peripheral NeuropathySemantic proximity Read ↗

Predictive biomarkers of chemotherapy-induced peripheral neuropathy: a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.